Pharmaceutical company · NVO

Novo Nordisk
clinical trial
pipeline

Registry checked

Published

Amycretin is linked to 14 distinct active studies, with 4 Phase 1, 10 Phase 3. Cagrilintide is linked to 11 distinct active studies, with 4 Phase 1, 7 Phase 3. Semaglutide is linked to 15 distinct active studies, with 2 Phase 1, 4 Phase 3, 2 Phase 4, 7 without a recorded phase.

Phase 2 study NCT07184632 in Overweight and Obesity lists estimated primary completion on 14 December 2026. Phase 2 study NCT07395687 in Overweight and Obesity lists estimated primary completion on 14 January 2027. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

144active trials
as lead sponsor
  • Phase 142
  • Phase 213
  • Phase 347
  • Phase 44
  • Phase not recorded38

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

1812 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Recruitment status
Not yet recruitingRecruiting

A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A

NCT07830732 · ClinicalTrials.gov
Recorded by ComplyRx
29 Oct 2026
Registry last updated
28 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-021000011
2026-10-030001011
2026-10-040000000
2026-10-050000111
2026-10-060000000
2026-10-071100021
2026-10-080010011
2026-10-090000000
2026-10-100001011
2026-10-110000000
2026-10-120000000
2026-10-131010021
2026-10-140000000
2026-10-150000000
2026-10-161000011
2026-10-171000011
2026-10-180000000
2026-10-190000000
2026-10-200001011
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-272110042
2026-10-280000000
2026-10-291001022
2026-10-300000000
2026-10-310000000
Type totals823411812 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Semaglutide

Ozempic · Rybelsus · Wegovy

15
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 12
  • Phase 20
  • Phase 34
  • Phase 42
  • Phase not recorded7
Studied condition
Cardiovascular Risk · Chronic Kidney Disease · Diabetes Mellitus, Type 2
Next primary completion
Not reported
Open drug

Amycretin

Canonical investigational asset

14
Active trials
11
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 14
  • Phase 20
  • Phase 310
  • Phase 40
  • Phase not recorded0
Studied condition
Diabetes Mellitus · Diabetes Mellitus, Type 2 · Heart Failure
Next primary completion
Not reported
Open drug

Cagrilintide

Canonical investigational asset

11
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 14
  • Phase 20
  • Phase 37
  • Phase 40
  • Phase not recorded0
Studied condition
Cardiovascular Disease · Obesity · Overweight
Next primary completion
11 May 2027 · estimated
Open drug

No treatment given

Canonical investigational asset

6
Active trials
0
Recruiting trials
Trial phases
Highest: Not reported
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 40
  • Phase not recorded6
Studied condition
Cardiovascular Disease (CVD) · Cardiovascular Risk · Chronic Kidney Disease
Next primary completion
Not reported
Open drug

Cagrisema

Canonical investigational asset

5
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 20
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Diabetes Mellitus, Type 2 · Obesity · Type 2 Diabetes
Next primary completion
01 March 2027 · estimated
Open drug

Zenagamtide

Canonical investigational asset

5
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
Cardiovascular Risk · Obesity · Overweight
Next primary completion
Not reported
Open drug

112 of 144 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 112 of 144 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Novo Nordisk trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity
NNC0662-0419

NCT07184632

Phase 2 · Active, not recruiting

Trial source and qualifications

A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

3 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 01 Oct 2025 · actual
    Primary completion: 14 Dec 2026 · estimated
    Study completion: 14 Dec 2026 · estimated

    2021202220232024202520262027202820292030
    A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
    UBT251

    NCT07395687

    Phase 2 · Recruiting

    Trial source and qualifications

    A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

    0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    No eligible observations recorded in the inspected period.

      Start: 02 Feb 2026 · actual
      Primary completion: 14 Jan 2027 · estimated
      Study completion: 18 Feb 2027 · estimated

      2021202220232024202520262027202820292030
      ONWARDS 11
      Insulin icodec

      NCT07076199

      Phase 3 · Active, not recruiting

      Trial source and qualifications

      A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      3 candidate observations · 1 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

      • status flip · Recorded 2026-09-01 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

      Start: 11 Aug 2025 · actual
      Primary completion: 25 Jan 2027 · estimated
      Study completion: 01 Mar 2027 · estimated

      2021202220232024202520262027202820292030
      ARTEMIS
      Ziltivekimab

      NCT06118281

      Phase 3 · Active, not recruiting

      Trial source and qualifications

      ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      4 candidate observations · 2 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

      • pc date moved · Recorded 2026-09-09 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
      • status flip · Recorded 2026-09-09 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

      Start: 25 Jun 2024 · actual
      Primary completion: 29 Jan 2027 · estimated
      Study completion: 29 Jan 2027 · estimated

      2021202220232024202520262027202820292030
      A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
      Cagrisema

      NCT07011667

      Phase 3 · Active, not recruiting

      Trial source and qualifications

      A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

      3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      3 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 03 Jun 2025 · actual
        Primary completion: 01 Mar 2027 · estimated
        Study completion: 17 Oct 2028 · estimated

        2021202220232024202520262027202820292030
        RENEW 1
        Cagrilintide

        NCT07220642

        Phase 3 · Active, not recruiting

        Trial source and qualifications

        Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

        2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        2 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 05 Nov 2025 · actual
          Primary completion: 11 May 2027 · estimated
          Study completion: 29 Jun 2027 · estimated

          2021202220232024202520262027202820292030

          Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

          6 selected of 47 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 10 actual primary completions, 0 untyped primary completions, 2 past estimates, 1 outside the horizon, 0 contradictory dates.

          04 / Therapeutic focus

          Where the activity is

          83

          active trials in Metabolic/Endocrine/Nutrition

          Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

          Active trials by primary therapeutic area

          • Metabolic/Endocrine/Nutrition83 trials
          • Cardiovascular13 trials
          • Haematology12 trials
          • Gastroenterology & Hepatology5 trials
          • Renal & Urology4 trials
          • Oncology3 trials
          • Genetic & Rare Disease2 trials
          • Womens Health2 trials
          • Pain & Musculoskeletal1 trials
          • Unmapped17 trials
          • Healthy volunteers2 trials

          Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

          06 / Related companies

          All companies

          Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

          Sources, scope and methodology

          ClinicalTrials.gov lead-sponsor scope

          Canonical current-owner attribution covers 1,430 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Novo Nordisk. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

          ClinicalTrials.gov

          Attribution coverage

          1,430 distinct registry candidates produced 1,430 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 18 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

          Indexed enrichment

          1,161 scoped records have indexed enrichment and 269 do not. Missing enrichment does not remove a trial from cohort counts.

          Scope observation

          The successful attribution check completed at 2026-11-01T01:43:38.979Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 059a31587e0a9a7a7994f303bc4dfc2e33d21db53d0764242d2fe11eedbc0545.

          Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

          Dated canonical-attribution snapshot: 1,430 mapped lead-sponsored clinical studies across all statuses. 1,161 have indexed enrichment, 269 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

          Keep following
          what matters.

          Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

          Build your watch

          Choose what to track in the watch builder.